Techcyte SureView Cervical Cytology System Clinical Validation Study
Multi-center, Two-arm Clinical Study Evaluating the Performance of the Techcyte Sureview Cervical Cytology System and Its Subsystems for the Assessment of Pap Tests
1 other identifier
observational
4,596
1 country
1
Brief Summary
The clinical study is a multi-center, retrospective, blinded, matched-pair, two-arm clinical study in which one test assessment and a control assessment of liquid-based cytology (LBC) pap tests are performed and compared to a reference. The control method is defined as the assessment of LBC pap tests performed by a cytotechnologist (CT) and/or cytopathologist (CP) using standard laboratory cervical cytology practices (i.e. a manual assessment) and following The Bethesda System for Reporting Cervical Cytology (TBS). The control method is referred to as the "standard method". The test method is referred to as the AI-assisted method. The AI-assisted method is defined as the assessment of the same LBC pap test as in the standard method, but with the Techcyte SureView Cervical Cytology System, which has pap tests being scanned on the Pramana SpectralHT Cubiq whole slide scanner, analyzed with the Techcyte Cervical Cytology Algorithm (TCCA) and presented on the Techcyte Viewer, using the Dell U3223QE Monitor for assessment by a CT/CP following the TBS. In addition, the time spent reviewing the samples with both methods will be measured such that the CT workload limit for AI-assisted assessment can be established. The LBC pap tests to be assessed in the clinical study must have been prepared with either ThinPrep® Pap Test (Hologic) or BD SurePath™ (Beckton, Dickinson and Company). The study aims to enroll for each preparation method an equal number of samples.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2024
CompletedFirst Submitted
Initial submission to the registry
January 6, 2025
CompletedFirst Posted
Study publicly available on registry
January 9, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedSeptember 4, 2025
September 1, 2025
1 year
January 6, 2025
September 2, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Sensitivity and specificity when comparing pap tests using the Techcyte SureView Cervical Cytology System
The primary objective of the study is to show that the assessment of LBC pap tests using the Techcyte SureView Cervical Cytology System, i.e. the AI-assisted method, is non-inferior to current standard practice, i.e., the standard method, at the LSIL+ threshold used for cytologic diagnosis (specimen adequacy and descriptive diagnosis) as defined by The Bethesda System for Reporting Cervical Cytology.
1 day
Interventions
Digital cervical cytology slide imaging system with artificial intelligence (AI) algorithm to be used for AI-assisted review
Eligibility Criteria
Samples collected in the United States
You may qualify if:
- Glass slides with cervical cytology specimens prepared with Hologic ThinPrep according to the pap test manufacturers Instructions for Use (IFU) using any of Hologic's processors (i.e. ThinPrep2000, ThinPrep 3000, ThinPrep 5000, ThinPrep Genesis). OR Glass slides with cervical cytology specimens prepared with BD SurePath according to the pap test manufacturers IFU using any of BD's processors (i.e. BD Totalys MultiProcessor, BD Totalys SlidePrep, BD PrepStain).
- Slide has the original diagnosis available.
- Slides that fit within the required sample size strata using the sample collection procedure.
- Glass slides with QR code, barcodes, or plain text labels.
- Glass slides with coverslips.
- Slides that are 5 years old or less, except where rare specimens require it. Those specimens will have to be reviewed for degradation per the sample collection procedure.
- Only one sample per patient and all are to be collected, processed and scanned.
You may not qualify if:
- Broken or cracked slides.
- Slides with air bubbles or scratched, cracked or broken/missing cover slips.
- Slides with markings (e.g., handwritten pen marking) that cannot be removed according to standard laboratory procedures.
- Degraded slides (ex: slides whose stains have lost color or specimens that are not intact).
- Glass slides with cervical cytology specimens prepared with methods other than Hologic ThinPrep or BD SurePath.
- Glass slides with specimens other than cervical cytology specimens.
- Slides from the same patient.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Techcyte, Inc.lead
Study Sites (1)
Techcyte
Orem, Utah, 84057, United States
Related Publications (1)
Nayar R, Wilbur DC. (eds), The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes. 3rd ed. Cham, Switzerland: Springer: 2015.
BACKGROUND
Biospecimen
Pap test slides prepared using the ThinPrep and SurePath methods. These slides are prepared prior to the study.
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 6, 2025
First Posted
January 9, 2025
Study Start
December 1, 2024
Primary Completion
December 1, 2025
Study Completion
December 1, 2025
Last Updated
September 4, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share